Firstly, the biological activity of the polar ingredient was profiled in related targets according to its clinical indications, including GPR109A (cardiovascular disease), β2-AR (asthma), NTSR (cancer), M3 (asthma) and GPR35 (inflammation). This evidence concerns the gene GPR35 and asthma.